JCI Insight (Nov 2023)

The semaphorin 3A/neuropilin-1 pathway promotes clonogenic growth of glioblastoma via activation of TGF-β signaling

  • Hye-Min Jeon,
  • Yong Jae Shin,
  • Jaehyun Lee,
  • Nakho Chang,
  • Dong-Hun Woo,
  • Won Jun Lee,
  • Dayna Nguyen,
  • Wonyoung Kang,
  • Hee Jin Cho,
  • Heekyoung Yang,
  • Jin-Ku Lee,
  • Jason K. Sa,
  • Yeri Lee,
  • Dong Geon Kim,
  • Benjamin W. Purow,
  • Yeup Yoon,
  • Do-Hyun Nam,
  • Jeongwu Lee

Journal volume & issue
Vol. 8, no. 21

Abstract

Read online

Glioblastoma (GBM) is the most lethal brain cancer with a dismal prognosis. Stem-like GBM cells (GSCs) are a major driver of GBM propagation and recurrence; thus, understanding the molecular mechanisms that promote GSCs may lead to effective therapeutic approaches. Through in vitro clonogenic growth-based assays, we determined mitogenic activities of the ligand molecules that are implicated in neural development. We have identified that semaphorin 3A (Sema3A), originally known as an axon guidance molecule in the CNS, promotes clonogenic growth of GBM cells but not normal neural progenitor cells (NPCs). Mechanistically, Sema3A binds to its receptor neuropilin-1 (NRP1) and facilitates an interaction between NRP1 and TGF-β receptor 1 (TGF-βR1), which in turn leads to activation of canonical TGF-β signaling in both GSCs and NPCs. TGF-β signaling enhances self-renewal and survival of GBM tumors through induction of key stem cell factors, but it evokes cytostatic responses in NPCs. Blockage of the Sema3A/NRP1 axis via shRNA-mediated knockdown of Sema3A or NRP1 impeded clonogenic growth and TGF-β pathway activity in GSCs and inhibited tumor growth in vivo. Taken together, these findings suggest that the Sema3A/NRP1/TGF-βR1 signaling axis is a critical regulator of GSC propagation and a potential therapeutic target for GBM.

Keywords